Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland. more
Time Frame | ITRM | Sector | S&P500 |
---|---|---|---|
1-Week Return | -30.28% | -2.82% | 0.15% |
1-Month Return | 33.78% | -4.22% | 1.78% |
3-Month Return | 78.38% | -9.52% | 8.7% |
6-Month Return | 65% | -3.45% | 12.24% |
1-Year Return | 17.86% | 5.62% | 30.9% |
3-Year Return | -72.21% | 3.8% | 30.19% |
5-Year Return | -95.45% | 39.68% | 91.72% |
10-Year Return | -98.97% | 105.02% | 203.2% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 37.00K | - | - | - | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | - | 161.00K | 2.10M | 1.80M | 1.75M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":7.65,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":85.55,"profit":true},{"date":"2023-12-31","value":83.17,"profit":true}] |
Gross Profit | 37.00K | (161.00K) | (2.10M) | (1.80M) | (1.75M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-435.14,"profit":false},{"date":"2021-12-31","value":-5686.49,"profit":false},{"date":"2022-12-31","value":-4864.86,"profit":false},{"date":"2023-12-31","value":-4729.73,"profit":false}] |
Gross Margin | 100.00% | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 102.06M | 32.13M | 24.54M | 30.38M | 47.47M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":31.48,"profit":true},{"date":"2021-12-31","value":24.04,"profit":true},{"date":"2022-12-31","value":29.77,"profit":true},{"date":"2023-12-31","value":46.51,"profit":true}] |
Operating Income | (102.02M) | (32.13M) | (24.54M) | (30.38M) | (47.47M) | [{"date":"2019-12-31","value":-10202100000,"profit":false},{"date":"2020-12-31","value":-3212600000,"profit":false},{"date":"2021-12-31","value":-2453700000,"profit":false},{"date":"2022-12-31","value":-3038300000,"profit":false},{"date":"2023-12-31","value":-4746800000,"profit":false}] |
Total Non-Operating Income/Expense | (1.53M) | (37.08M) | (71.88M) | (16.11M) | 8.77M | [{"date":"2019-12-31","value":-17.41,"profit":false},{"date":"2020-12-31","value":-422.97,"profit":false},{"date":"2021-12-31","value":-819.84,"profit":false},{"date":"2022-12-31","value":-183.77,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (102.69M) | (51.26M) | (90.86M) | (44.13M) | (37.76M) | [{"date":"2019-12-31","value":-10268600000,"profit":false},{"date":"2020-12-31","value":-5126300000,"profit":false},{"date":"2021-12-31","value":-9085900000,"profit":false},{"date":"2022-12-31","value":-4413300000,"profit":false},{"date":"2023-12-31","value":-3775800000,"profit":false}] |
Income Taxes | 444.00K | 743.00K | 705.00K | 301.00K | 613.00K | [{"date":"2019-12-31","value":59.76,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":94.89,"profit":true},{"date":"2022-12-31","value":40.51,"profit":true},{"date":"2023-12-31","value":82.5,"profit":true}] |
Income After Taxes | (103.13M) | (52.01M) | (91.56M) | (44.43M) | (38.37M) | [{"date":"2019-12-31","value":-10313000000,"profit":false},{"date":"2020-12-31","value":-5200600000,"profit":false},{"date":"2021-12-31","value":-9156400000,"profit":false},{"date":"2022-12-31","value":-4443400000,"profit":false},{"date":"2023-12-31","value":-3837100000,"profit":false}] |
Income From Continuous Operations | (103.13M) | (52.01M) | (91.56M) | (44.43M) | (31.10M) | [{"date":"2019-12-31","value":-10313000000,"profit":false},{"date":"2020-12-31","value":-5200600000,"profit":false},{"date":"2021-12-31","value":-9156400000,"profit":false},{"date":"2022-12-31","value":-4443400000,"profit":false},{"date":"2023-12-31","value":-3109900000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (103.13M) | (52.01M) | (91.56M) | (44.43M) | (38.37M) | [{"date":"2019-12-31","value":-10313000000,"profit":false},{"date":"2020-12-31","value":-5200600000,"profit":false},{"date":"2021-12-31","value":-9156400000,"profit":false},{"date":"2022-12-31","value":-4443400000,"profit":false},{"date":"2023-12-31","value":-3837100000,"profit":false}] |
EPS (Diluted) | (106.65) | (38.55) | (11.55) | (2.39) | (2.77) | [{"date":"2019-12-31","value":-10665,"profit":false},{"date":"2020-12-31","value":-3855,"profit":false},{"date":"2021-12-31","value":-1155,"profit":false},{"date":"2022-12-31","value":-239,"profit":false},{"date":"2023-12-31","value":-277,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ITRM | |
---|---|
Cash Ratio | 0.78 |
Current Ratio | 0.85 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ITRM | |
---|---|
ROA (LTM) | -73.35% |
ROE (LTM) | -555.68% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ITRM | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 1.72 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -0.72 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ITRM | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 1349.79 |
P/B | 6.03 |
Price/FCF | NM |
EV/R | 105.22 |
EV/Ebitda | 0.55 |
Iterum Therapeutics PLC (ITRM) share price today is $1.98
Yes, Indians can buy shares of Iterum Therapeutics PLC (ITRM) on Vested. To buy Iterum Therapeutics PLC from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ITRM stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Iterum Therapeutics PLC (ITRM) via the Vested app. You can start investing in Iterum Therapeutics PLC (ITRM) with a minimum investment of $1.
You can invest in shares of Iterum Therapeutics PLC (ITRM) via Vested in three simple steps:
The 52-week high price of Iterum Therapeutics PLC (ITRM) is $3.02. The 52-week low price of Iterum Therapeutics PLC (ITRM) is $0.81.
The price-to-earnings (P/E) ratio of Iterum Therapeutics PLC (ITRM) is
The price-to-book (P/B) ratio of Iterum Therapeutics PLC (ITRM) is 6.03
The dividend yield of Iterum Therapeutics PLC (ITRM) is 0.00%
The market capitalization of Iterum Therapeutics PLC (ITRM) is $54.48M
The stock symbol (or ticker) of Iterum Therapeutics PLC is ITRM